Pre‐miR‐27a rs895819 polymorphism and risk of diffuse large B‐cell lymphoma

Tang, Weiyan; Xu, Haonan; Ma, Dawei; Ma, Rong; Wu, Jianqiu; Yu, Xinnian; Feng, Jifeng; Liu, Qizhan

doi:10.1002/jcla.23088

Cited by 5 publications

(4 citation statements)

References 28 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the mechanism of the rs895819 SNV and its effect on its expression is unknown. Previous studies suggested that the rs895819 SNV alters the stability and/or processing of miR-27a; however, these results are conflicting, with some studies showing increased miR-27a expression [13,34], others showing decreased miR-27a expression [27,35,36], and one showing no effect of the rs895819 SNV on miR-27a expression [37]. Similarly, conflicting studies have shown a decrease, an increase, and no association between carriers of the rs895819 SNV and the risk of various cancers [16][17][18]25,38].…”

Section: Discussionmentioning

confidence: 99%

Genetic Variation in miR-27a Is Associated with Fluoropyrimidine-Associated Toxicity in Patients with Dihydropyrimidine Dehydrogenase Variants after Genotype-Guided Dose Reduction

Medwid,

Wigle,

Ross

et al. 2023

IJMS

View full text Add to dashboard Cite

Dihydropyrimidine dehydrogenase (DPYD) is the rate-limiting enzyme involved in the metabolism of fluoropyrimidine-based chemotherapy. However, single-nucleotide variants (SNVs) in DPYD only partially explain fluoropyrimidine-induced toxicity. The expression of DPYD has previously been shown to be regulated by microRNA-27a (miR-27a) and a common miR-27a SNV (rs895819) has been associated with an increased risk of toxicity in patients harboring a DPYD variant who received standard fluoropyrimidine dosing. We investigated if the miR-27a rs895819 SNV was associated with toxicity in DPYD wildtype patients and carriers of DPYD variants who received a reduced dose. The regulation of DPYD using miR-27a was investigated in HepG2 cells utilizing a miR-27a mimic. miR-27a overexpression decreased DPYD mRNA expression compared to control cells (p < 0.0001). In a cohort of patients that received pre-emptive DPYD genotyping, 45 patients had a DPYD variant and 180 were wildtype. Patients heterozygous for rs895819 had an increased risk of toxicity, which was seen in both patients who were wildtype for DPYD variants (OR (95%CI) = 1.99 (1.00–3.99)) and DPYD variant carriers (OR (95%CI) = 8.10 (1.16–86.21)). Therefore, miR-27a rs895819 may be a clinically relevant predictor of fluoropyrimidine-associated toxicities. Furthermore, toxicity was more profound in DPYD variant carriers, even after DPYD genotype-guided dose reduction. This suggests that patients may benefit from miR-27a genotyping to guide fluoropyrimidine dosing.

show abstract

Section: Discussionmentioning

confidence: 99%

Genetic Variation in miR-27a Is Associated with Fluoropyrimidine-Associated Toxicity in Patients with Dihydropyrimidine Dehydrogenase Variants after Genotype-Guided Dose Reduction

Medwid,

Wigle,

Ross

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Besides environment and living habits, such as a sedentary lifestyle, smoking, and drinking, genetic variation also plays an important role in the development of CRC 6,7 . Rs895819 polymorphism is a single nucleotide polymorphism (SNP) located in the terminal loop of pre‐miR‐27a and has been reported to be associated with the risk of cancer, such as non‐small cell lung cancer, cervical cancer, diffuse large B‐cell lymphoma, and CRC 8‐11 . Although several studies have suggested that the rs895819 polymorphism was associated with CRC risk in Chinese population, these results need to be further confirmed 11‐13 .…”

Section: Introductionmentioning

confidence: 99%

“…6,7 Rs895819 polymorphism is a single nucleotide polymorphism (SNP) located in the terminal loop of pre-miR-27a and has been reported to be associated with the risk of cancer, such as non-small cell lung cancer, cervical cancer, diffuse large B-cell lymphoma, and CRC. [8][9][10][11] Although several studies have suggested that the rs895819 polymorphism was associated with CRC risk in Chinese population, these results need to be further confirmed. [11][12][13] Hence, we conducted a case-control study and pooled analysis to investigate the effect of the rs895819 polymorphism on CRC risk in Chinese population.…”

mentioning

confidence: 99%

The association of miR‐27a rs895819 polymorphism with colorectal cancer risk in Chinese population

Zhang

Han

Zhu

et al. 2020

Clinical Laboratory Analysis

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are a class of small non-coding RNAs participating in the regulation of the expression of downstream genes by targeting the 3′-untranslated region (3′-UTR) of the corresponding mRNAs. Growing evidence suggests that miRNAs play a major role in the development of cancer. 1 For instance, miR-27a, located on chromosome 19, has been demonstrated to be abnormally expressed in many types of cancer, including colorectal cancer (CRC). 2-4 Gao et al found that miR-27a highly expressed in patients with colon cancer could enhance proliferation and invasion of colon cancer cells. 4 Liu et al 5 found that miR-27a could promote proliferation, migration, and invasion of CRC by targeting FAM172A and might serve as a diagnostic and prognostic biomarker of CRC. These findings indicated that miR-27a could function as an oncogene in CRC.

show abstract

“…However, the exact pathogenesis of NHL is still not fully understood but many risk factors reported that are involved in lymphoma development. Environments as well as genetic factors are two major risk factors for lymphoma (Zhong et al, 2019;Tang et al, 2020).…”

Section: Introductionmentioning

confidence: 99%